Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)

China · Delayed Price · Currency is CNY

8.57

-0.17 (-1.95%)

Sep 10, 2026, 2:35 PM CST

SHA:603520 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,462	2,446	2,350	2,196	2,131	2,000
Revenue Growth	1.85%	4.06%	7.02%	3.04%	6.57%	46.29%
Gross Profit	477.23	472.85	430.39	507.69	502.59	744.81
Operating Income	88.76	83.4	62.77	151.57	139.14	441.12
Net Income	21.02	10.23	-49.1	44.23	-75.85	323.75
Earnings Per Share	0.04	0.02	-0.12	0.13	-0.22	0.94
EPS Growth	-	-	-	-	-	31.60%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
CMO/CDMO	40.54
Contrast Agent	2,135
Others	22.97
Quinolone	36.25
Total	2,234

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	287.7	415.34	603.35	565.16	662.44	845.9
Total Debt	2,852	2,966	2,659	3,056	2,782	1,908
Net Cash (Debt)	-2,564	-2,550	-2,056	-2,491	-2,120	-1,062
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-4.88	-4.99	-5.02	-7.32	-6.15	-3.08

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-12.46	3.67	193.5	44.55	-78.37	508.84
Capital Expenditures	-203.72	-269.2	-480.62	-266.22	-472.18	-303.88
Free Cash Flow	-216.18	-265.53	-287.12	-221.67	-550.56	204.96
Free Cash Flow Growth	-	-	-	-	-	861.68%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	19.38%	19.33%	18.31%	23.12%	23.58%	37.24%
Operating Margin	3.60%	3.41%	2.67%	6.90%	6.53%	22.06%
Pretax Margin	0.88%	0.29%	-2.43%	2.07%	-3.07%	19.77%
Profit Margin	0.85%	0.42%	-2.09%	2.01%	-3.56%	16.19%
FCF Margin	-8.78%	-10.86%	-12.22%	-10.09%	-25.83%	10.25%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.300	0.300	0.150	-	0.500	0.357
Dividend Per Share Growth	100.00%	100.00%	-	-	40.02%	0%
Dividend Yield	3.43%	3.27%	1.80%	-	2.71%	0.82%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	218.33	402.90	-	109.03	-	49.07
Forward PE	30.14	29.84	17.38	23.53	23.90	37.04
P/FCF Ratio	-	-	-	-	-	77.51
PS Ratio	1.56	1.69	1.62	2.20	3.14	7.94